WO2001032204A3 - Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression - Google Patents

Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression Download PDF

Info

Publication number
WO2001032204A3
WO2001032204A3 PCT/US2000/030223 US0030223W WO0132204A3 WO 2001032204 A3 WO2001032204 A3 WO 2001032204A3 US 0030223 W US0030223 W US 0030223W WO 0132204 A3 WO0132204 A3 WO 0132204A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammalian
nucleic acid
gene promoter
vaccine compositions
antigen expression
Prior art date
Application number
PCT/US2000/030223
Other languages
French (fr)
Other versions
WO2001032204A2 (en
Inventor
Scott Umlauf
Lee K Roberts
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Priority to EP00975544A priority Critical patent/EP1240343A2/en
Priority to JP2001534408A priority patent/JP2004522403A/en
Priority to CA002389680A priority patent/CA2389680A1/en
Priority to AU13585/01A priority patent/AU1358501A/en
Publication of WO2001032204A2 publication Critical patent/WO2001032204A2/en
Publication of WO2001032204A3 publication Critical patent/WO2001032204A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Polynucleotides encoding at least one immunizing antigen whose expression is controlled by a promoter derived from a gene encoding a co-stimulatory molecule are provided. The polynucleotides may also encode adjuvants. Compositions comprising at least one immunizing agent and at least one cytokine that enhance dendritic cell stimulation and/or survival are also provided. Methods for eliciting an immune response against the immunizing agent are also provided. The method includes the steps of administering the polynucleotides and, optionally, co-administering an adjuvant.
PCT/US2000/030223 1999-11-03 2000-11-01 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression WO2001032204A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00975544A EP1240343A2 (en) 1999-11-03 2000-11-01 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
JP2001534408A JP2004522403A (en) 1999-11-03 2000-11-01 Nucleic acid vaccine compositions having a mammalian CD80 / CD86 gene promoter driving antigen expression
CA002389680A CA2389680A1 (en) 1999-11-03 2000-11-01 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
AU13585/01A AU1358501A (en) 1999-11-03 2000-11-01 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43298399A 1999-11-03 1999-11-03
US09/432,983 1999-11-03

Publications (2)

Publication Number Publication Date
WO2001032204A2 WO2001032204A2 (en) 2001-05-10
WO2001032204A3 true WO2001032204A3 (en) 2002-07-25

Family

ID=23718377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030223 WO2001032204A2 (en) 1999-11-03 2000-11-01 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression

Country Status (5)

Country Link
EP (1) EP1240343A2 (en)
JP (1) JP2004522403A (en)
AU (1) AU1358501A (en)
CA (1) CA2389680A1 (en)
WO (1) WO2001032204A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164819A1 (en) 2001-11-20 2005-05-19 Deml, Ludwig, Dr. Method for identifying target epitopes of the T-cell-mediated immune response and for detecting epitope-specific T cells
GB0226717D0 (en) * 2002-11-15 2002-12-24 Collen Res Foundation D DNA vaccination
JP2008504219A (en) * 2003-12-11 2008-02-14 シドニー キンメル キャンサー センター Methods for raising immunity against an antigen

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
WO1996014855A1 (en) * 1994-11-15 1996-05-23 Agracetus, Inc. Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997042337A1 (en) * 1996-05-02 1997-11-13 Glaxo Group Limited Gene expression in monocytes and macrophages
WO1998028332A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2; compositions and uses thereof
WO1998046083A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
WO1998052581A1 (en) * 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
WO1996014855A1 (en) * 1994-11-15 1996-05-23 Agracetus, Inc. Method for inducing humoral and cellular immune responses utilizing intracellular delivery of peptide-coated microparticles
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1997032987A1 (en) * 1996-03-08 1997-09-12 University Of Toronto Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization
WO1997042337A1 (en) * 1996-05-02 1997-11-13 Glaxo Group Limited Gene expression in monocytes and macrophages
WO1998028332A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2; compositions and uses thereof
WO1998046083A1 (en) * 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
WO1998052581A1 (en) * 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AZEVEDO V ET AL: "Main features of DNA-based immunization vectors", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 32, no. 2, February 1999 (1999-02-01), pages 147 - 153, XP000993271 *
FONG T ET AL: "Identification of a promoter element that regulates tissue-specific expression of the human CD80 (B7.1) gene", J. IMMUNOL, vol. 157, no. 10, 15 November 1996 (1996-11-15), pages 4442 - 4450, XP002174926 *
HARMS J ET AL: "Regulation of transgene expression in genetic immunization", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 32, no. 2, February 1999 (1999-02-01), pages 155 - 162, XP000993272 *
MORITA A ET AL: "ROLES OF LANGERHANS CELLS IN GENETIC IMMUNIZATION", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IR, vol. 20, no. 1, May 1999 (1999-05-01), pages 39 - 52, XP000982406, ISSN: 0923-1811 *
See also references of EP1240343A2 *
TACKET C ET AL: "Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device", VACCINE, vol. 17, no. 22, 16 July 1999 (1999-07-16), pages 2826 - 2829, XP002174927 *
XIANG Z ET AL: "The effect of interferon-gamma on genetic immunization", VACCINE, vol. 15, no. 8, June 1997 (1997-06-01), pages 896 - 898, XP002174925 *

Also Published As

Publication number Publication date
CA2389680A1 (en) 2001-05-10
JP2004522403A (en) 2004-07-29
EP1240343A2 (en) 2002-09-18
AU1358501A (en) 2001-05-14
WO2001032204A2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
WO1999058658A3 (en) Expression vectors for stimulating an immune response and methods of using the same
Tüting et al. DNA immunization targeting the skin: molecular control of adaptive immunity
Pascolo Vaccination with messenger RNA (mRNA)
EP3294326A1 (en) Prime-boost regimens involving administration of at least one mrna construct
Sun et al. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination
EP0879284A4 (en) Gene expression vectors which generate an antigen specific immune response and methods of using the same
JP2003528887A5 (en)
DE69929444D1 (en) CPG COMPOSITIONS, SAPONIN ADJUVANTIES, AND METHOD OF USE THEREOF
WO1997049423A3 (en) Liposomal influenza vaccine composition and method
WO1999008706A8 (en) Recombinant porcine adenovirus vector
CA2385655A1 (en) Dna immunization against chlamydia infection
WO2005030136A3 (en) Tumor vaccine
Weth et al. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination
WO2001032204A3 (en) Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression
WO2003059379A3 (en) Immunogenic carcinoembryonic antigen (cea)
WO1998017814A3 (en) Gene expression and delivery systems and uses
Weiss et al. Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
WO2002053176A3 (en) An autologous anti-cancer vaccine
Weiner Immunostimulatory DNA sequences and cancer therapy
IL149415A0 (en) Adjuvanted genetic vaccines
NO20005481L (en) CD80, CD86, CD28 and CTLA-4 nucleic acid and cat polypeptides
WO2001068829A3 (en) Genetically stable cholera vaccines
Schmidt et al. MIDGE vectors and dSLIM immunomodulators: DNA-based molecules for gene therapeutic strategies
WO2003000894A9 (en) Polynucleotide vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2389680

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 534408

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000975544

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000975544

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642